Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.

The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.

Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.

Antibody-drug conjugates, GLP-1 receptor agonists and cell/gene therapies propelled a big increase in clinical trial registrations in China last year, but why do sponsors sometimes remain reluctant to actually start studies?